Clinical Trials Browser

Withdrawn × Lymphoma × ibritumomab tiuxetan × Clear all

NCT00414089 2016-02-15

Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL

Phase 2 Withdrawn

Lymphoma